Entities / Company
Illumina.
American company that develops systems for the analysis of genetic variation
- Reports this week
- 3
- Active events
- 2
- Connections
- 167
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
-
JPMorgan lowered its price target on Illumina stock as directors and SVPs sold shares.Some support2 reports
-
Illumina reported that its Q2 revenue and EPS surpassed market expectations on July 30, 2026.Some support2 reports
-
Citigroup issued a rating report on Illumina, while MarketBeat aggregated the stock rating data.Some support5 reports
-
Director Keith Meister sold shares of Illumina stock on October 15, 2026.Some support1 report
-
Illumina and eBay were discussed in the context of their economic moats.Some support1 report
-
Illumina and OmniAb were noted to operate within the healthcare/biotechnology sector.Some support1 report
One to three months ago
-
Analysis suggests that both Moderna and Illumina stocks are currently overvalued.Some support1 report
-
VOO index undergoes changes including adding Illumina and Bloom Energy, while Builders FirstSource is removed. Separately, Fisher Investments promotes VOO strategies.Some support2 reports
-
Illumina achieved S&P 500 inclusion via index rebalancing, with the company headquartered in San Diego, CA.Some support1 report
-
Illumina is accelerating the adoption of its technologies in clinical markets across Canada.Some support1 report
-
Several companies, including Everpure and Bloom Energy Corporation, are scheduled to be added to the S&P 500 index, replacing existing members.Some support2 reports
-
Illumina and MindWalk Holdings Corp. have partnered, with both companies operating in the field of AI-enabled drug discovery.Some support1 report
-
Meiji Yasuda Life Insurance Co increased its stake in Illumina shares and sold stock under a trading plan.Some support1 report
-
TD Cowen raised its price objective on Illumina stock on August 26, 2026.Some support1 report
-
Several companies, including Guardant Health and Myriad Genetics, are competing in the liquid biopsy market.Some support1 report1 development inside
-
MedLife and Illumina developed a full workflow in Romania using the NovaSeq X Plus platform.Some support1 report
-
Illumina is offering its services in the US, UK, and Singapore, and providing analyst ratings.Some support1 report
-
Illumina and Bio-Rad Laboratories collaborate on advanced life science technologies.Some support1 report1 development inside
Gone quiet
No new reports in 90+ days-
Illumina reported its financial results, showing a year-on-year revenue growth of 9.4% on August 4, 2026.Some support1 report
-
Canaccord raised its price target for Illumina shares, noting that revenue growth driven by clinical customers and NovaSeq X adoption is key to expansion goals.Some support2 reports1 development inside
-
Morgan Stanley grew its holdings in Illumina, and PNC Financial Services Group increased its holdings in Illumina shares on July 29, 2026.Some support1 report
-
NIH grant uncertainty is causing delays in academic projects involving various research entities.Some support1 report1 development inside
-
Fifth Third Bancorp increased its stake in Illumina stock on July 18, 2026.Some support1 report
-
Illumina faces challenges from China's entity list and potential upside from Trump-era tariffs.Some support2 reports
-
Barclays raised its price target on Illumina, which appointed an Eli Lilly executive to its board, while Roche launched a cheaper gene sequencing machine.Some support2 reports
-
Daiwa Securities Group upgraded its stock rating and price target for Illumina on June 29, 2026, while Royal Bank of Canada began coverage with an outperform rating.Some support4 reports
-
The acquisition of SomaLogic by Illumina is expanding Illumina's capabilities into proteomics and precision medicine.Speculative5 reports
-
Illumina and Eli Lilly are strategically aligning through corporate appointments, including appointing an executive from Eli Lilly to another company's board.Some support1 report
-
Illumina SVP sold 700 shares of the company.Some support1 report
-
Royal Bank of Canada initiated coverage on Illumina stock.Some support1 report
-
Morgan Stanley and Norges Bank boosted their holdings in Illumina during the 4th quarter.Some support1 report
-
Illumina faces regulatory uncertainties in China.Some support1 report
-
Illumina faces restricted instrument exports to China, prompting regulatory changes and analyst scrutiny from Bank of America.Speculative1 report
-
Illumina, AbbVie, Abbott Laboratories, Qiagen, and Eli Lilly are major players in the US personalized medicine market and are investing in related R&D.Some support1 report1 development inside
-
Emerging competition from Roche is a near-term concern for Illumina.Speculative1 report
-
Market growth in personalized medicine is being driven by demand, involving major players like Roche and Illumina.Some support1 report
-
Government support is fueling biotech innovation involving Illumina and Roche.Some support1 report
-
RingCentral, Hershey, and Illumina were analyzed for cash-producing stock risks on August 22, 2025.Some support2 reports
-
Standard BioTools acquired SomaLogic, retaining reagent rights for Illumina, following a strategic sale of SomaLogic to Illumina.Speculative1 report
-
Illumina appointed Jacob Thaysen as CEO and Director.Speculative1 report
-
Illumina announced an agreement to acquire SomaLogic on September 3, 2025, utilizing SomaLogic's technology for new assays.Some support2 reports2 developments inside
-
Grail was formed following a spin-off from Illumina, and Morgan Stanley reiterated its 'Equal Weight' stance on the companies.Speculative3 reports
-
Illumina was ranked second overall in the United States as of July 10, 2025.Some support1 report
-
Illumina announced its results from San Diego.Some support1 report
-
Illumina and Agenus were noted to operate within the same industry.Some support1 report
-
Illumina and Qiagen are noted as top players in the tumor profiling market experiencing growth in Europe.Some support1 report
-
Illumina and Harmony Biosciences Holdings, Inc. were classified as stocks in the Medical-Biomedical and Genetics sector on July 15, 2025.Some support1 report
-
Sea expanded its services across Southeast Asia, with profitability analyses involving Sprinklr and Illumina.Some support2 reports
-
Illumina and DaVita HealthCare reported positive ESP figures on July 22, 2025.Some support1 report
-
Cathie Wood invested in Illumina's disruptive life sciences.Some support2 reports
-
Illumina sold genomic-sequencing systems with software vulnerabilities, leading to an FDA warning.Some support1 report
-
Baron Funds highlighted Illumina in its investor letter on August 5, 2025.Some support1 report
-
Illumina reported that Europe contributed 29.3% of its total revenue in August 2025.Some support1 report
-
Illumina, Pacific Biosciences, Microsoft, and Monster Beverage were mentioned as thematic investing winners in the life sciences tools and services segment.Some support3 reports
-
Illumina, Twist Bioscience, Ginkgo Bioworks, Amyris, Cargill, Moderna, and Vertex Pharmaceuticals are all key players in the AI in Synthetic Biology Market.Some support2 reports
-
GRAIL reported an impairment of assets related to its acquisition of Illumina.Some support2 reports
-
Illumina Inc. is based in San Diego, CA.Some support1 report
-
Rate cut speculation on August 14, 2025, benefited growth sectors, including healthcare companies like Clover Health, Surgery Partners, Illumina, and Bruker.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Illumina
Events traced to Illumina, step by step, newest firstAround Illumina this week
News at the entities that move Illumina most-
Nasdaq StructuralAn AI stock sell-off impacted Nasdaq on November 5, 2026, following the election results.Moves Illumina
-
China StructuralNova Scotia is exporting seafood to China, which has extended tariff-free access for Canadian products.Moves Illumina
-
FDA StructuralThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves Illumina
-
Fifth Third Bancorp TransactionalFifth Third Bancorp boosted its position in the Vanguard Russell 1000 Growth ETF, while ETF Portfolio Partners Inc. bought a new stake in the ETF.Moves Illumina
-
Morgan Stanley TransactionalSurrozen utilized conference platforms hosted by Morgan Stanley in South San Francisco on September 1, 2026.Moves Illumina
-
SEC StructuralDirector Arne Wilhelmsen sold shares of Royal Caribbean Cruises Ltd. and disclosed the transaction to the SEC.Moves Illumina
Connections
The 38 strongest of 167, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SomaLogic Structural
Illumina acquired SomaLogic and integrated its technology into its multiomics and proteomics ecosystem.
-
GRAIL Structural
GRAIL maintains a structural financial relationship with Illumina as its largest shareholder and through ongoing royalty obligations.
-
Nasdaq Structural
Illumina is a publicly traded company whose shares are listed and traded on the Nasdaq exchange.
-
Jakob Wedel Transactional
Jakob Wedel, identified as an SVP, sold 700 shares of Illumina under a trading plan.
-
Fifth Third Bancorp Transactional
Fifth Third Bancorp increased its stake in Illumina stock.
-
China Structural
Illumina's operations and revenue are subject to formal regulatory restrictions and uncertainties imposed by China.
-
Europe Shared context
Illumina operates within the European market, which contributes a significant portion of its total revenue and is subject to market growth and sales fluctuations.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial coverage, ratings, and price targets for Illumina stock, influencing market sentiment.
Show all 38 connections
-
FDA Structural
FDA provides regulatory approval necessary for Illumina's commercialization of CDx indications.
-
MedLife Structural
MedLife relies on Illumina's NovaSeq X Plus platform for its operations.
-
Morgan Stanley Transactional
Morgan Stanley increased its holdings in Illumina, resulting in a 66.0% boost during the fourth quarter.
-
Keith Meister Transactional
Keith Meister, a director, sold a significant portion of his shares in Illumina stock.
-
Citigroup Operational
Citigroup provided financial rating reports and adjusted target prices for Illumina.
-
VOO Structural
VOO includes Illumina in its holdings, and Illumina's market performance influences the index VOO tracks.
-
Singapore Structural
Illumina has established a regional head office and provides sequencing services within Singapore.
-
Eli Lilly and Company Structural
Illumina received an executive appointment from Eli Lilly and Company, establishing a formal governance link.
-
Norges Bank Transactional
Norges Bank purchased a new stake in Illumina during the 4th quarter.
-
SEC Structural
Illumina is subject to regulatory oversight by the SEC regarding insider transactions and disclosures.
-
Hoffmann-La Roche Operational
Illumina and Hoffmann-La Roche are actively competing in the gene sequencing and liquid biopsy markets.
-
Leerink partners Mentioned together
Leerink partners provides financial research reports and price targets regarding Illumina.
-
Bio-Rad Laboratories Operational
The companies collaborate on advanced life science technologies.
-
Donald Trump Shared context
Illumina's business model is exposed to the potential policy impacts of Trump-era tariffs and trade policies.
-
TD Cowen Mentioned together
TD Cowen provides analyst ratings and price targets that influence the market sentiment and stock price of Illumina.
-
TipRanks Mentioned together
TipRanks provides financial analysis and reports on Illumina's technology perception.
-
Daiwa Securities Group Mentioned together
Daiwa Securities Group provided a stock rating upgrade and price target for Illumina.
-
Bloom Energy Mentioned together
Both Illumina and Bloom Energy are included as components of the S&P 500 index.
-
Latin America Shared context
Latin America serves as the market context for Illumina's sales performance.
-
Ark Invest Transactional
Ark Invest reduced its holdings in Illumina during a portfolio review.
-
Investor's Business Daily Mentioned together
Investor's Business Daily published an analysis suggesting Illumina stock was overvalued.
-
Lilly Research Laboratories Shared context
The company leverages the research institution's expertise, and the institution benefits from industry context, establishing a shared strategic focus.
-
Middle East Shared context
Illumina's sales performance is reported within the context of the Middle East market.
-
Twilio Mentioned together
Both companies were observed to sell off late on earnings reports.
-
S&P Mentioned together
Illumina's revenue performance was evaluated against consensus estimates provided by S&P analysts.
-
MarketBeat Mentioned together
MarketBeat aggregates and provides analyst ratings and price targets for Illumina.
-
eBay Mentioned together
Both Illumina and eBay were discussed thematically in the context of possessing economic moats.
-
San Diego Shared context
Illumina operates out of its headquarters located in San Diego, California.
-
Barclays Mentioned together
Barclays analysts provide financial coverage and price targets for Illumina.
-
Chicago Shared context
The provided evidence describes Illumina's activities at ASCO but does not mention Chicago.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
4 events- JPMorgan lowered its price target on Illumina stock as directors and SVPs sold shares.
- Director Keith Meister sold shares of Illumina stock on October 15, 2026.
- Illumina and eBay were discussed in the context of their economic moats.
- Illumina and OmniAb were noted to operate within the healthcare/biotechnology sector.
September 2026
6 events- Analysis suggests that both Moderna and Illumina stocks are currently overvalued.
- VOO index undergoes changes including adding Illumina and Bloom Energy, while Builders FirstSource is removed. Separately, Fisher Investments promotes VOO strategies.
- Illumina achieved S&P 500 inclusion via index rebalancing, with the company headquartered in San Diego, CA.
- Illumina is accelerating the adoption of its technologies in clinical markets across Canada.
- Several companies, including Everpure and Bloom Energy Corporation, are scheduled to be added to the S&P 500 index, replacing existing members.
- Illumina and MindWalk Holdings Corp. have partnered, with both companies operating in the field of AI-enabled drug discovery.
Show 3 earlier months
August 2026
5 events- Meiji Yasuda Life Insurance Co increased its stake in Illumina shares and sold stock under a trading plan.
- TD Cowen raised its price objective on Illumina stock on August 26, 2026.
- MedLife and Illumina developed a full workflow in Romania using the NovaSeq X Plus platform.
- Illumina is offering its services in the US, UK, and Singapore, and providing analyst ratings.
- Illumina reported its financial results, showing a year-on-year revenue growth of 9.4% on August 4, 2026.
July 2026
6 events- Illumina reported that its Q2 revenue and EPS surpassed market expectations on July 30, 2026.
- Citigroup issued a rating report on Illumina, while MarketBeat aggregated the stock rating data.
- Illumina and Bio-Rad Laboratories collaborate on advanced life science technologies.
- Morgan Stanley grew its holdings in Illumina, and PNC Financial Services Group increased its holdings in Illumina shares on July 29, 2026.
- Fifth Third Bancorp increased its stake in Illumina stock on July 18, 2026.
- Illumina faces challenges from China's entity list and potential upside from Trump-era tariffs.
June 2026
38 events- Illumina acquired SomaLogic for cash and royalties.
- Several companies, including Guardant Health and Myriad Genetics, are competing in the liquid biopsy market.
- Canaccord raised its price target for Illumina shares, noting that revenue growth driven by clinical customers and NovaSeq X adoption is key to expansion goals.
- NIH grant uncertainty is causing delays in academic projects involving various research entities.
- Barclays raised its price target on Illumina, which appointed an Eli Lilly executive to its board, while Roche launched a cheaper gene sequencing machine.
- Daiwa Securities Group upgraded its stock rating and price target for Illumina on June 29, 2026, while Royal Bank of Canada began coverage with an outperform rating.
- The acquisition of SomaLogic by Illumina is expanding Illumina's capabilities into proteomics and precision medicine.
- Illumina and Eli Lilly are strategically aligning through corporate appointments, including appointing an executive from Eli Lilly to another company's board.
- Illumina SVP sold 700 shares of the company.
- Royal Bank of Canada initiated coverage on Illumina stock.
- Morgan Stanley and Norges Bank boosted their holdings in Illumina during the 4th quarter.
- Illumina faces regulatory uncertainties in China.
- Illumina faces restricted instrument exports to China, prompting regulatory changes and analyst scrutiny from Bank of America.
- Illumina, AbbVie, Abbott Laboratories, Qiagen, and Eli Lilly are major players in the US personalized medicine market and are investing in related R&D.
- Emerging competition from Roche is a near-term concern for Illumina.
- Market growth in personalized medicine is being driven by demand, involving major players like Roche and Illumina.
- Government support is fueling biotech innovation involving Illumina and Roche.
- RingCentral, Hershey, and Illumina were analyzed for cash-producing stock risks on August 22, 2025.
- Standard BioTools acquired SomaLogic, retaining reagent rights for Illumina, following a strategic sale of SomaLogic to Illumina.
- Illumina appointed Jacob Thaysen as CEO and Director.
- Illumina announced an agreement to acquire SomaLogic on September 3, 2025, utilizing SomaLogic's technology for new assays.
- Grail was formed following a spin-off from Illumina, and Morgan Stanley reiterated its 'Equal Weight' stance on the companies.
- Illumina was ranked second overall in the United States as of July 10, 2025.
- Illumina announced its results from San Diego.
- Illumina and Agenus were noted to operate within the same industry.
- Illumina and Qiagen are noted as top players in the tumor profiling market experiencing growth in Europe.
- Illumina and Harmony Biosciences Holdings, Inc. were classified as stocks in the Medical-Biomedical and Genetics sector on July 15, 2025.
- Sea expanded its services across Southeast Asia, with profitability analyses involving Sprinklr and Illumina.
- Illumina and DaVita HealthCare reported positive ESP figures on July 22, 2025.
- Cathie Wood invested in Illumina's disruptive life sciences.
- Illumina sold genomic-sequencing systems with software vulnerabilities, leading to an FDA warning.
- Baron Funds highlighted Illumina in its investor letter on August 5, 2025.
- Illumina reported that Europe contributed 29.3% of its total revenue in August 2025.
- Illumina, Pacific Biosciences, Microsoft, and Monster Beverage were mentioned as thematic investing winners in the life sciences tools and services segment.
- Illumina, Twist Bioscience, Ginkgo Bioworks, Amyris, Cargill, Moderna, and Vertex Pharmaceuticals are all key players in the AI in Synthetic Biology Market.
- GRAIL reported an impairment of assets related to its acquisition of Illumina.
- Illumina Inc. is based in San Diego, CA.
- Rate cut speculation on August 14, 2025, benefited growth sectors, including healthcare companies like Clover Health, Surgery Partners, Illumina, and Bruker.